J & J’s pharmaceutical business posts strong sales according to 2014 fourth quarter report

WASHINGTON - Jan. 21, 2015 - PRLog -- Johnson and Johnson (J & J) reported strong sales for its pharmaceutical business segment with worldwide revenue amounting to $32.3 billion for the full-year 2014,  which is a 14.9% increase compared to 2013. Domestic sales were up by 25% and worldwide sales increased by 15%.

New products along with the company’s existing pharmaceutical portfolio were the key drivers for the sales growth. These include: OLYSIO®/SOVRIAD®(simeprevir), combo treatment of chronic hepatitis C in adult patients; XARELTO® (rivaroxaban), an oral anticoagulant; ZYTIGA®(abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA® (canagliflozin), for the treatment of adults with type 2 diabetes; and IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved to treat certain B-cell malignancies, or blood cancers.

Other key contributors that provided positive momentum to the operational sales growth include: Breakthrough biologic STELARA® (ustekinumab) for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI®/SIMPONI ARIA® (golimumab) and REMICADE®(infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.

“2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our Pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our Medical Devices business and are continuing our market leadership with iconic brands in our Consumer business,” said Alex Gorsky, Chairman and Chief Executive Officer.  “I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world.”

CANDIDATES WHO WANT TO BREAK INTO A PHARMACEUTICAL SALES CAREER!

With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/